重组人血管内皮抑制素联合雷替曲塞与奥沙利铂治疗晚期大肠癌的临床效果

摘要

ObjectiveTo explore the clinical efficacy of recombinant human endostatin combined with raltitrexed and oxaliplatin in treatment of advanced large intestine cancer.MethodFrom November 2008 to March 2010, 60 patients with advanced large intestine cancer were selected as the research objects. According to the random number table method, they were randomly divided into observation group and control group, 30 cases in each group. Patients in observation group were treated with recombinant human endostatin combined with raltitrexed and oxaliplatin, patients in control group were treated with raltitrexed and oxaliplatin. The efficacy, immune function indexes (CD4+, CD3+, CD4+/CD8+), tumor markers (CEA, CA19-9, CA125) levels, adverse reactions and KPS scores were compared between the two groups.Result The effective rate of observation group was signiifcantly higher than control group (P<0.05). There were no signiifcant differences in CD3+, CD4+ and CD4+/CD8+ before treatment between the two groups (P>0.05). After treatment, CD3+ and CD4+ were signiifcantly improved, and CD4+ improved in observation group were signiifcantly better than control group (P<0.05). The CD4+/CD8+ in observation group were signiifcantly higher than before treatment (P<0.05), the control group had no signiifcant change (P>0.05). There was no signiifcant difference in the incidence of adverse reactions between the two groups (P>0.05). There were no signiifcant differences in KPS scores and tumor markers between the two groups before treatment (P>0.05). The level of tumor markers in the two groups was not signiifcantly different (P>0.05), and the KPS score of observation group was signiifcantly better than control group (P<0.05).ConclusionRecombinant human endostatin combined with raltitrexed and oxaliplatin can effectively improve the prognosis and immune function of patients, does not increase the adverse reactions, worthy of clinical application.%目的：探讨重组人血管内皮抑制素联合雷替曲塞与奥沙利铂治疗晚期大肠癌的临床效果。方法选取本院2008年11月至2010年3月收治的晚期大肠癌患者60例为研究对象，采用随机数表法将其分为观察组与对照组，每组各30例。观察组患者采用重组人血管内皮抑制素联合雷替曲塞与奥沙利铂治疗，对照组患者采用雷替曲塞与奥沙利铂治疗。比较两组患者疗效、治疗前后免疫功能指标（CD3+、CD4+、CD4+/CD8+）、肿瘤标志物[癌胚抗原（CEA）、糖类抗原19-9（CA19-9）、糖类抗原125（CA125）]水平、不良反应发生情况及KPS评分。结果观察组患者治疗有效率明显高于对照组（P＜0.05）。两组患者治疗前CD3+、CD4+、CD4+/CD8+比值比较差异均无显著性（P＞0.05）；治疗后CD3+、CD4+水平均较治疗前明显改善，且观察组患者CD4+水平改善明显优于对照组（P＜0.05），观察组患者CD4+/CD8+比值较治疗前明显升高（P＜0.05），对照组无明显变化（P＞0.05）。两组患者各不良反应发生率比较差异均无显著性（P＞0.05）。两组患者治疗前KPS评分及肿瘤标志物水平比较差异均无显著性（P＞0.05）；两组患者肿瘤标志物水平比较差异无显著性（P＞0.05），观察组患者KPS评分明显优于对照组（P＜0.05）。结论重组人血管内皮抑制素联合雷替曲塞与奥沙利铂可有效改善患者预后及免疫功能，不增加不良反应，值得临床推广应用。